Clinical Trials Logo

Secondary Adrenal Insufficiency clinical trials

View clinical trials related to Secondary Adrenal Insufficiency.

Filter by:
  • None
  • Page 1

NCT ID: NCT05827965 Active, not recruiting - Clinical trials for Fasting, Intermittent

Ramadan Fasting in Secondary Adrenal Insufficiency Patients

Start date: March 1, 2023
Phase: N/A
Study type: Interventional

Intermittent Ramadan fasting was associated with a risk of complications in patients with adrenal insufficiency. A risk stratification with recommendations (lifestyle and drug adjustment) for fasting in these patients has been recently published. So, this prospective interventional study was carried out to evaluated these recommendations. Patients with secondary adrenal insufficiency and willing to fast Ramadan were included. Before Ramadan, patients underwent a clinical examination and were educated for lifestyle measures and the schedule of glucocorticoid replacement therapy was adjusted. The occurrence of complications and the number of fasted days during the month of Ramadan 2023 were reported and compared with those of Ramadan 2022.

NCT ID: NCT02277587 Completed - Clinical trials for Primary Adrenal Insufficiency

Dual RElease Hydrocortisone Versus conventionAl Glucocorticoid replaceMent Therapy in Hypocortisolism (DREAM)

DREAM
Start date: March 2014
Phase: Phase 4
Study type: Interventional

This is a randomized, controlled, open, three-armed, multi-centre study designed to compare the effects of dual-release hydrocortisone preparations versus conventional glucocorticoid therapy on anthropometric parameters, metabolic syndrome, infectious, immunological profile, cardiovascular system, bone mass and quality of life in patients affected by primary or secondary adrenal insufficiency.

NCT ID: NCT00561236 Completed - Clinical trials for Secondary Adrenal Insufficiency

Does Intravitreal Injection of Triamcinolone Acetonide Impairs the Adrenal Function

Start date: April 2007
Phase: N/A
Study type: Observational

The use of intravitreal corticosteroids in the management ocular inflammatory diseases has recently gained widespread acceptance. The purpose of this study is to determine if the use of intravitreal triamcinolone is associated with suppression of endogenous cortisol production, as generally admitted for patients treated with oral or parenteral corticosteroid therapy.